Apoptotic and proliferative index after alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia

Urologia Internationalis

Volumn 69, Issue 4, 2002, Pages 287-292

  Erdoǧru, Tibet ^a,b   Ciftcioglu, M Akif ^a   Emreoglu, Ibrahim ^a   Usta, Mustafa F ^a   Koksal, Turker ^a   Ozbilim, Gülay ^a   Gulkesen, K Hakan ^a   Baykara, Mehmet ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

^b AKDENIZ UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Alpha adrenoceptor antagonists; Apoptosis; Cell proliferation; Finasteride; Prostate

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLINE; DNA FRAGMENT; DOXAZOSIN; FINASTERIDE; KI 67 ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ENZYME INHIBITOR; PRAZOSIN; TERAZOSINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DRUG EFFICACY; EPITHELIUM CELL; HUMAN; HUMAN TISSUE; MALE; NICK END LABELING; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; STROMA; CELL DIVISION; DRUG EFFECT; MIDDLE AGED; PATHOLOGY;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL DIVISION; DOXAZOSIN; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; MIDDLE AGED; PRAZOSIN; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES;

EID: 0036436814     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066120     Document Type: Article

References (17)

1. Kyprianou N, Litvak JP, Borkowski A, Alexander R, Jacobs SC: Induction of prostate apoptosis by doxazosin in benign prostatic hyperplasia. J Urol 1998;159:1810-1815.
2. Monda JM, Oesterling JE: Medical treatment of benign prostatic hyperplasia: 5-α reductase inhibitors and α-adrenergic antagonists. Mayo Clin Proc 1993;68:670-679.
3. Lepor H, Williford OW, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJ: The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. N Engl J Med 1996;335:533-539.
4. Pheel DM: Basic biological studies of prostate disease: Translation to clinical application. AUA Update Ser 1996;XV: lesson 29.
5. Farnsworth WE: Prostate stroma: Physiology. Prostate 1999;38:60-72.
6. Kyprianou N, Tu H, Jacobs SC: Apoptotic versus proliferative activities in human benign prostatic hyperplasia. Hum Pathol 1996;27:668-675.
7. Yang G, Timme TL, Park SH, Wu X, Wyllie MG, Thompson TC: Transforming growth factor β1 transduced mouse prostate reconstructions. II. Induction of apoptosis by doxazosin. Prostate 1997;33:157-163.
8. Oesterling JE, el Etreby MF, Gormley GF, Imperato-McGinley JL, Roehrborn CG, Schroder FH, Tunn UW: Endocrin therapies for BPH: Scientific rationale, clinical results and patient selection. Prog Clin Biol Res 1994;386:231-250.
9. Janknegt RA, Chapple CR for the Doxazosin Study Groups: Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Eur Urol 1993;24:319-326.
10. Chon JK, Borkowski A, Partin AW, Isaacs JT, Jacobs SC, Kyprianou N: α1-Adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1998;161:2002-2008.
11. Kyprianou N, Isaacs JT: Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1998;122:552-562.
12. Cardillo M, Berchem G, Tarkington MA, Krajewski S, Karajewski M, Reed JC, Tehan T, Ortega L, Iage J, Gelmann EP: Resistance to apoptosis and upregulation of bcl-2 in benign prostatic hyperplasia after androgen deprivation. J Urol 1997;158:212-216.
13. Buttyan R: Apoptosis/programmed cell death in urology. AUA Update Ser 1999, XVIII: lesson 34.
14. Lekas E, Engstrand C, Bergh A, Damper JE: Transient ischemia induces apoptosis in the ventral prostate of the rat. Urol Res 1999;27:174-179.
15. Shabsigh A, Chang DT, Heitjan DF, Kiss A, Olsson CA, Puchner PJ, Buttyan R: Rapid reduction in blood flow to the rat ventral prostate gland after castration: Preliminary evidence that androgens influence prostate size by regulating blood flow to the prostate gland and prostatic endothelial cell survival. Prostate 1998;36:201-206.
16. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, Norman RW, Lazier CB, Rowden G: Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology 1995;136:741-748.
17. Claus S, Berges R, Senge T, Schulze H: Cell kinetics in epithelium and stroma of benign prostatic hyperplasia. J Urol 1997;158:217-221.